These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade. Padfield GJ; AlAhmari L; Lieve KV; AlAhmari T; Roston TM; Wilde AA; Krahn AD; Sanatani S Heart Rhythm; 2016 Feb; 13(2):609-13. PubMed ID: 26416620 [No Abstract] [Full Text] [Related]
16. [Tachycardia with wide QRS. Limitations of electrocardiographic criteria in patients treated with anti-arrhythmia agents]. Le Davay M; Victor J; Dupuis JM; Merheb M; Tran P; Tadeï A Ann Cardiol Angeiol (Paris); 1994 May; 43(5):253-5. PubMed ID: 8074416 [TBL] [Abstract][Full Text] [Related]
19. Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports. van der Werf C; Wilde AA Europace; 2011 Jan; 13(1):11-3. PubMed ID: 20851823 [No Abstract] [Full Text] [Related]
20. Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia. Watanabe H; Steele DS; Knollmann BC Circ Res; 2011 Sep; 109(6):712-3. PubMed ID: 21885838 [No Abstract] [Full Text] [Related] [Next] [New Search]